Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.
Hepatitis/MASH
Latest News
Advertisement
CME Content
Advertisement
The FDA today amended its breakthrough therapy designation for an experimental hepatitis C drug combination.
Study finds benefits from reduced absenteeism and improved workplace productivity.
Height can impact wait times for transplantation and overall mortality.
Blood test predicts which patients will respond to interferon.
Promising results from generic formulation of drug used post-transplant to reduce the risk of organ rejection.
Investigational 3-drug combination cleared the virus in 93% of treatment-naïve patients.
Direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir showed high rates of sustained virologic response after 12 weeks.
Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.
HIV and HCV co-infected patients with HALS found to be more likely to develop cirrhosis.
Liver damage is the bane of HIV-infected patients' existence.
A look back at the top stories on Specialty Pharmacy Times from May 4 to May 8.
Cancer rates significantly greater compared with non-infected individuals.
Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.
Cirrhosis-related death rates drop across all age brackets.
Therapy shows promise in treatment of hepatitis C genotype-1 mono-infected patients.
Raplixa reduces time needed to stop bleeding during surgery.
Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.
Merck's once-daily treatment regimen of grazoprevir and elbasvir may bring added competition to HCV drug market.
Despite increases in liver cirrhosis hospitalizations over the years, the cirrhotic inpatient death rate has dropped 41%.
An antiviral and anti-cancer drug combination was 100% effective in preclinical trials.
HIV-infected men may be more sensitive to alcohol's effects.
Record number of orphan drugs approved in 2014.
Orphan drugs and breakthrough therapies last year comprised the highest number of new medications approved since 2001.
Co-administration of amiodarone with simeprevir and sofosbuvir combination is not recommended.
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
2
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5
